血清可溶性CD36水平与2型糖尿病并非酒精性脂肪肝关系的研究进展

被引：5

作者：

王福慧 ^{[1
]}

曹岚 ^{[1
]}

李博 ^{[2
]}

金凤表 ^{[1
]}

侯瑞田 ^{[2
]}

机构：

[1] 承德医学院附属医院内分泌科

[2] 承德医学院附属医院心内科

来源：

中华实用诊断与治疗杂志 | 2017年 / 31卷 / 07期

关键词：

2型糖尿病; 非酒精性脂肪性肝病; 可溶性CD36; 动脉粥样硬化;

D O I：

暂无

中图分类号：

R575.5 [肝代谢障碍]; R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

近年来2型糖尿病(type 2 diabetes mellitus,T2DM)并非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)发病率逐年增加。血清可溶性CD36(soluble CD36,sCD36)与胰岛素抵抗、炎症反应、糖脂代谢、动脉粥样硬化的发生密切相关,在T2DM并NAFLD的发生、发展中发挥重要作用,但有关sCD36与T2DM并NAFLD关系的研究较少。本文就血清sCD36水平与T2DM、NAFLD、T2DM并NAFLD关系的研究进展作一综述。

引用

页码：726 / 728

页数：3

共 13 条

[1]

NAFLD: A multisystem disease.[J].Christopher D. Byrne;Giovanni Targher.Journal of Hepatology.2015, 1

[2]

Free Fatty Acid Uptake in Humans With CD36 Deficiency [J].

Hames, Kazanna C. ;

Vella, Adrian ;

Kemp, Bradley J. ;

Jensen, Michael D. .

DIABETES, 2014, 63 (11) :3606-3614

[3]

Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease [J].

Garcia-Monzon, Carmelo ;

Lo Iacono, Oreste ;

Crespo, Javier ;

Romero-Gomez, Manuel ;

Garcia-Samaniego, Javier ;

Fernandez-Bermejo, Miguel ;

Dominguez-Diez, Agustin ;

Rodriguez de Cia, Javier ;

Saez, Alicia ;

Luis Porrero, Jose ;

Vargas-Castrillon, Javier ;

Chavez-Jimenez, Enrique ;

Soto-Fernandez, Susana ;

Diaz, Ainhoa ;

Gallego-Duran, Rocio ;

Madejon, Antonio ;

Eugenia Miquilena-Colina, Maria .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (01) :65-73

[4]

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.[J].Howard C. Masuoka;Naga Chalasani.Annals of the New York Academy of Sciences.2013, 1

[5]

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes.[J].Alessandra Puddu;Fran?ois Mach;Alessio Nencioni;Giorgio Luciano Viviani;Fabrizio Montecucco;Dennis D. Taub.Mediators of Inflammation.2013,

[6]

CD36 as a target to prevent cardiac lipotoxicity and insulin resistance.[J].Jan F.C. Glatz;Yeliz Angin;Laura K.M. Steinbusch;Robert W. Schwenk;Joost J.F.P. Luiken.Prostaglandins; Leukotrienes and Essential Fatty Acids (PLEFA).2012,

[7]

Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients [J].